Uterine Fibroids — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for uterine fibroids. 10 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
10
Active US patents
47/100
Avg vulnerability
$421M
Annual revenue covered

Originators in Uterine Fibroids

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

MYOVANT SCIENCES 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating uterine fibroids. Each bar = one year. Y-axis scaled to peak year (6 patents).

1
29
2
33
1
36
6
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Orgovyx
relugolix
 MYOVANT SCIENCES 10 47 $421M 2029-01-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12336990 Orgovyx method of use 75 2037-09-29
12097198 Orgovyx method of use 75 2037-09-29
12144809 Orgovyx method of use 75 2037-09-29
11583526 Orgovyx method of use 70 2037-09-29
10786501 Orgovyx method of use 62 2037-09-29
10449191 Orgovyx method of use 62 2037-09-29
10350170 Orgovyx formulation 42 2036-02-25
7300935 Orgovyx composition of matter 17 2029-01-28
12325714 Orgovyx composition of matter 17 2033-09-27
11795178 Orgovyx composition of matter 12 2033-09-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11795178 Orgovyx composition of matter 12 2033-09-27
12325714 Orgovyx composition of matter 17 2033-09-27
7300935 Orgovyx composition of matter 17 2029-01-28
10350170 Orgovyx formulation 42 2036-02-25
10449191 Orgovyx method of use 62 2037-09-29
10786501 Orgovyx method of use 62 2037-09-29
11583526 Orgovyx method of use 70 2037-09-29
12144809 Orgovyx method of use 75 2037-09-29
12336990 Orgovyx method of use 75 2037-09-29
12097198 Orgovyx method of use 75 2037-09-29

Related